Photo from archive.org
Article history: Received 27 February 2017 Received in revised form 11 March 2017 Accepted 26 April 2017 ed. Secondly, the evidence of PEA associated with disease severity was unwarranted. Finally,… Click to show full abstract
Article history: Received 27 February 2017 Received in revised form 11 March 2017 Accepted 26 April 2017 ed. Secondly, the evidence of PEA associated with disease severity was unwarranted. Finally, the cost-effectiveness of PEA as a new biomarker also needs further investigations. In conclusion, a significant amount of work is required to apply PEA as a new biomarker to predict coronary dysfunction in clinical practice.
Keywords:
pea promising;
promising biomarker;
biomarker;
palmitoylethanolamide pea;
coronary dysfunction
Journal Title: International journal of cardiology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: International journal of cardiology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!